CMMB - Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10 2024 | Benzinga
—"Breaking New Ground: Expert Perspectives on Primary Sclerosing Cholangitis" Will Feature Clinical, Academic and Patient Advocacy Leaders Discussing PSC Disease Management and Evolving Views on Clinical Development—
TEL AVIV, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced it will host a live key opinion leader (KOL) virtual event on primary sclerosing cholangitis (PSC) on Wednesday, April 10, 2024 at 10:00 AM ET. To register, click here.
The event, "Breaking New Ground: Expert Perspectives on Primary Sclerosing Cholangitis," will feature Christopher Bowlus, MD (UC Davis Health), Ricky Safer (PSC Partners Seeking a Cure), and Massimo Pinzani, MD, PhD, (UCL Institute for Liver and Digestive Health, UPMC ISMETT), who will provide clinical and patient perspectives on PSC, a devastating rare liver disease with no FDA-approved therapies. They will discuss the urgent need for new PSC treatments and emerging developments that could facilitate new drug approvals.
Chemomab's co-founder, CEO & CSO Adi Mor, PhD and CMO Matt Frankel, MD, will provide an overview of the CM-101 Phase 2 PSC clinical trial that will report topline results midyear 2024. CM-101 is a dual mechanism first-in-class monoclonal antibody that neutralizes CCL24, a soluble protein that is a key driver of inflammatory and fibrotic pathways central to PSC and other fibro-inflammatory diseases.
A Q&A session will follow the presentations.
About Christopher Bowlus, MD
Chris Bowlus, MD is the Lena Valente Professor and Chief of the Division of Gastroenterology and Hepatology at the University of California Davis School of Medicine. Dr. Bowlus has an active research program bridging the basic and clinical aspects of PSC and primary biliary cholangitis (PBC), with the goal of bringing ...